Cargando…
A Study on Central Lymph Node Metastasis in 543 cN0 Papillary Thyroid Carcinoma Patients
Background. Papillary thyroid carcinoma (PTC) with central lymph node metastases (CLNMs) is common. The objective of this study was to investigate the incidence and risk factors of lymph node metastasis patients with PTC. Patients and Methods. Between January 2013 and February 2015, a retrospective...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834155/ https://www.ncbi.nlm.nih.gov/pubmed/27127507 http://dx.doi.org/10.1155/2016/1878194 |
_version_ | 1782427449814941696 |
---|---|
author | Yan, Huanhuan Zhou, Xiaoqian Jin, Hui Li, Xiang Zheng, Miao Ming, Xu Wang, Ruitao Liu, Jun |
author_facet | Yan, Huanhuan Zhou, Xiaoqian Jin, Hui Li, Xiang Zheng, Miao Ming, Xu Wang, Ruitao Liu, Jun |
author_sort | Yan, Huanhuan |
collection | PubMed |
description | Background. Papillary thyroid carcinoma (PTC) with central lymph node metastases (CLNMs) is common. The objective of this study was to investigate the incidence and risk factors of lymph node metastasis patients with PTC. Patients and Methods. Between January 2013 and February 2015, a retrospective study of 543 patients with PTC undergoing hemithyroidectomy or total thyroidectomy with routine central lymph node dissection (CLND) was analyzed. Clinicopathologic risk factors for CLNM were studied using univariate and multivariate analysis by SPSS 22.0 software. Results. The incidence of CLNMs in PTC patients was 38.1% (207/543). In the multivariate analysis, male gender (p < 0.001, OR: 1.984), age <45 years (p < 0.001, OR: 1.934), bilaterality (p = 0.006, OR: 1.585), tumor size ≥0.25 cm (p = 0.001, OR: 7.655), and external extension (p = 0.001, OR: 7.579) were independent risk factors of CLNMs. Furthermore, in PTC patients with tumor size <0.25 cm, all 7 males and 21 patients with unilaterality were not found to have CLNMs. Conclusions. CLNMs are prevalent in the PTC patients with the following risk factors: male gender, age <45 years, bilaterality, tumor size ≥0.25 cm, and external extension. PTC patients with tumor size <0.25 cm, male patients, and patients with unilateral lesion could be considered safe from CLNMs. |
format | Online Article Text |
id | pubmed-4834155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-48341552016-04-28 A Study on Central Lymph Node Metastasis in 543 cN0 Papillary Thyroid Carcinoma Patients Yan, Huanhuan Zhou, Xiaoqian Jin, Hui Li, Xiang Zheng, Miao Ming, Xu Wang, Ruitao Liu, Jun Int J Endocrinol Research Article Background. Papillary thyroid carcinoma (PTC) with central lymph node metastases (CLNMs) is common. The objective of this study was to investigate the incidence and risk factors of lymph node metastasis patients with PTC. Patients and Methods. Between January 2013 and February 2015, a retrospective study of 543 patients with PTC undergoing hemithyroidectomy or total thyroidectomy with routine central lymph node dissection (CLND) was analyzed. Clinicopathologic risk factors for CLNM were studied using univariate and multivariate analysis by SPSS 22.0 software. Results. The incidence of CLNMs in PTC patients was 38.1% (207/543). In the multivariate analysis, male gender (p < 0.001, OR: 1.984), age <45 years (p < 0.001, OR: 1.934), bilaterality (p = 0.006, OR: 1.585), tumor size ≥0.25 cm (p = 0.001, OR: 7.655), and external extension (p = 0.001, OR: 7.579) were independent risk factors of CLNMs. Furthermore, in PTC patients with tumor size <0.25 cm, all 7 males and 21 patients with unilaterality were not found to have CLNMs. Conclusions. CLNMs are prevalent in the PTC patients with the following risk factors: male gender, age <45 years, bilaterality, tumor size ≥0.25 cm, and external extension. PTC patients with tumor size <0.25 cm, male patients, and patients with unilateral lesion could be considered safe from CLNMs. Hindawi Publishing Corporation 2016 2016-04-03 /pmc/articles/PMC4834155/ /pubmed/27127507 http://dx.doi.org/10.1155/2016/1878194 Text en Copyright © 2016 Huanhuan Yan et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Yan, Huanhuan Zhou, Xiaoqian Jin, Hui Li, Xiang Zheng, Miao Ming, Xu Wang, Ruitao Liu, Jun A Study on Central Lymph Node Metastasis in 543 cN0 Papillary Thyroid Carcinoma Patients |
title | A Study on Central Lymph Node Metastasis in 543 cN0 Papillary Thyroid Carcinoma Patients |
title_full | A Study on Central Lymph Node Metastasis in 543 cN0 Papillary Thyroid Carcinoma Patients |
title_fullStr | A Study on Central Lymph Node Metastasis in 543 cN0 Papillary Thyroid Carcinoma Patients |
title_full_unstemmed | A Study on Central Lymph Node Metastasis in 543 cN0 Papillary Thyroid Carcinoma Patients |
title_short | A Study on Central Lymph Node Metastasis in 543 cN0 Papillary Thyroid Carcinoma Patients |
title_sort | study on central lymph node metastasis in 543 cn0 papillary thyroid carcinoma patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834155/ https://www.ncbi.nlm.nih.gov/pubmed/27127507 http://dx.doi.org/10.1155/2016/1878194 |
work_keys_str_mv | AT yanhuanhuan astudyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients AT zhouxiaoqian astudyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients AT jinhui astudyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients AT lixiang astudyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients AT zhengmiao astudyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients AT mingxu astudyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients AT wangruitao astudyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients AT liujun astudyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients AT yanhuanhuan studyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients AT zhouxiaoqian studyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients AT jinhui studyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients AT lixiang studyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients AT zhengmiao studyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients AT mingxu studyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients AT wangruitao studyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients AT liujun studyoncentrallymphnodemetastasisin543cn0papillarythyroidcarcinomapatients |